Technology
Health
Pharmaceutical

PLx Pharma

$5.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (3.53%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PLx Pharma and other stocks, options, ETFs, and crypto commission-free!

About

PLx Pharma Inc. Common Stock, also called PLx Pharma, is a late-stage specialty pharmaceutical company, which engages in the development of clinically validated and patent-protected PLxGuard delivery system. Read More Its products include Vazalore 325 mg and PL1200 Ibuprofen 200 mg. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Houston, TX.

Employees
15
Headquarters
Houston, Texas
Founded
2002
Market Cap
50.06M
Price-Earnings Ratio
Dividend Yield
Average Volume
19.60K
High Today
$5.72
Low Today
$5.30
Open Price
$5.68
Volume
3.65K
52 Week High
$6.44
52 Week Low
$1.00

Collections

Technology
Health
Pharmaceutical
2014 IPO
US
North America
Female CEOs

News

Yahoo FinanceMay 10

PLx Pharma Inc. Reports First Quarter 2019 Results

Company submits briefing package to U.S. Food and Drug Administration HOUSTON, May 10, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced today certain financial and operational results for the three months...

9
NasdaqMay 3

PLx Pharma (PLXP) Expected to Beat Earnings Estimates: Should You Buy?

27
Yahoo FinanceMay 2

PLx Pharma Inc. to Discuss 2019 First Quarter Financial Results on May 10, 2019 Conference Call

HOUSTON, May 02, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced today that the Company will release its 2019 first quarter financial results on Friday, May 10, 2019, before the U.S. financial markets ope...

3

Earnings

-$0.45
-$0.40
-$0.36
-$0.31
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.33 per share
Actual
-$0.36 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.